195 related articles for article (PubMed ID: 25175352)
41. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
[TBL] [Abstract][Full Text] [Related]
42. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
43. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
[TBL] [Abstract][Full Text] [Related]
44. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
45. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
[TBL] [Abstract][Full Text] [Related]
46. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
Furusato B; van Leenders GJ; Trapman J; Kimura T; Egawa S; Takahashi H; Furusato M; Visakorpi T; Hano H
Pathol Int; 2011 Jul; 61(7):409-14. PubMed ID: 21707844
[TBL] [Abstract][Full Text] [Related]
48. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
49. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
50. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
51. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
52. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
54. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
55. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
[TBL] [Abstract][Full Text] [Related]
56. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
[TBL] [Abstract][Full Text] [Related]
57. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract][Full Text] [Related]
59. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
[TBL] [Abstract][Full Text] [Related]
60. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
